Table 2.
Antiviral activity of FD001 and its analogs against SARS-CoV and MERS-CoV PsV infection.
| Compound | CC50 (µM) | IC50 (µM) | SI | EC50 (µM) | SI |
|---|---|---|---|---|---|
| CC50/IC50 | CC50/EC50 | ||||
| SARS-CoV PsV infection in hACE2-293T cells | |||||
| FD001 | 28.84 ± 1.24 | 0.18 ± 0.02 | 160.22 | 1.58 ± 0.21 | 18.25 |
| FD007 | 33.11 ± 1.02 | 0.11 ± 0.01 | 301.00 | 1.54 ± 0.14 | 21.50 |
| FD008 | 23.44 ± 0.78 | 0.05 ± 0.01 | 468.80 | 0.19 ± 0.02 | 123.37 |
| FD009 | 17.37 ± 0.64 | 0.03 ± 0.01 | 579.00 | 0.12 ± 0.01 | 144.75 |
| FD010 | 20.42 ± 1.00 | 0.29 ± 0.03 | 70.41 | 0.19 ± 0.03 | 107.47 |
| FD012 | 12.30 ± 0.34 | 0.02 ± 0.01 | 615.00 | 0.12 ± 0.01 | 102.50 |
| FD013 | 18.62 ± 0.23 | 0.05 ± 0.01 | 372.40 | 0.10 ± 0.01 | 186.20 |
| MERS-CoV PsV infection in Huh-7 cells | |||||
| FD001 | 42.65 ± 1.31 | 0.29 ± 0.03 | 147.07 | 1.12 ± 0.16 | 38.08 |
| FD007 | >50 | 0.20 ± 0.03 | >250 | 0.89 ± 0.09 | >56.18 |
| FD008 | 38.90 ± 1.22 | 0.31 ± 0.02 | 125.48 | 0.69 ± 0.13 | 56.38 |
| FD009 | 27.54 ± 1.43 | 0.28 ± 0.02 | 98.36 | 0.29 ± 0.02 | 94.97 |
| FD010 | 44.67 ± 1.26 | 0.12 ± 0.01 | 372.25 | 0.04 ± 0.01 | 1116.75 |
| FD012 | 18.62 ± 0.35 | 0.11 ± 0.01 | 169.27 | 0.05 ± 0.01 | 372.40 |
| FD013 | 30.90 ± 0.63 | 0.05 ± 0.01 | 618.00 | 0.03 ± 0.01 | 1030.00 |
The IC50 of mAb 33G4 was 0.03 μg/mL for inhibiting SARS-CoV PsV infection in hACE2-293T cells, while the IC50 of mAb m336 was 0.006 μg/mL for inhibiting MERS-CoV PsV infection in Huh-7 cells.